YourLawyer.com 1-800-LAW-INFO (1-800-529-4636)
Injured by Vioxx?
Parker Waichman Alonso LLP Has Been Representing Vioxx Heart Attack & Stroke Victims Nationwide Since 2001. Merck & Co. removed its blockbuster arthritis drug Vioxx (Generic: Rofecoxib) from the market worldwide because new data from a clinical trial found an increased risk of heart attack and stroke. Merck decided to remove the drug from the market on September 30, 2004, after data from the trial showed an increased risk of heart attack, stroke, blood clots and other cardiovascular complications. Parker & Waichman has been the choice for Vioxx victims in need of a pharmaceutical liability lawyer since 2001.
Vioxx Recall TimelineLancet Says Vioxx Should Have Been Recalled in 2000
Documents May Show Merck Knew About Vioxx Side Effects
The data comes from a three-year study aimed at showing that Vioxx at a 25 milligram dose prevents recurrence of polyps in the colon and rectum. The trial was stopped after Merck discovered the higher heart risk compared to patients taking dummy pills.
Before the withdrawal of Vioxx, the FDA announced that patients taking Vioxx have a 50 percent greater chance of heart attacks and sudden cardiac death. he study, presented at an epidemiologists conference, also found patients taking the highest recommended daily dosage of Vioxx had three times the risk of heart attack and sudden cardiac death as those not taking standard painkillers.
The popular and heavily advertised arthritis drugs Vioxx and Celebrex have been linked by researchers to an increase in the risk of blood clots, heart attacks and strokes.The study from the Cleveland Clinic appeared in the Journal of the American Medical Association and was based on an analysis of previous clinical trials. Celebrex and Vioxx are projected to produce U.S. sales greater than $6 billion this year.
In a study of more than 8,000 patients that compared the COX-2 inhibitor rofecoxib Vioxx) with the traditional NSAID naproxen, the risk of cardiovascular problems, including heart attack,chest pain related to heart disease, stroke, sudden death and blood clots, was more than two times higher in the rofecoxib group than in the naproxen group.
Vioxx, like Celebrex, is classified as a COX-2 inhibitor, or coxib. COX-2 inhibitors, like older drugs such as ibuprofen and naproxen, are nonsteroidal anti-inflammatory drugs, or NSAIDs. Older NSAIDs reduce inflammation by blocking an enzyme called COX-2, but they also block another enzyme called COX-1. This enzyme helps protect the lining of the stomach, so blocking COX-2 can cause stomach irritation. COX-2 inhibitors only block COX-2, leaving the stomach-protecting COX-1 alone.
In 2000, Merck spent $160.8 million on direct to consumer Vioxx marketing. Many people are familiar with Vioxx television advertisements featuring the famous figure skater Dorothy Hamill. Sid Wolfe, a physician and director of the Health Research Group of the advocacy group Public Citizen in Washington, D.C. said "Dorothy Hamill doesn't tell people they have a four times higher risk of a heart attack on Vioxx."
If you or a loved one took Vioxx and suffered side effects, please fill out the form at the right for a free case evaluation by a qualified drug side effects attorney.
VioxxRSS Feed
Speedy Drug Approvals Put Patients at Risk
Dec 3, 2008 | Parker Waichman Alonso LLP
A prominent researcher has charged that pressure to quickly bring new drugs to market may be endangering patients. To often, quick approval means a drug's dangerous side effects are missed, and only discovered years after a medication has been on the market.In an article he wrote for The British Medical Journal, Dr. David Kao of the University of Colorado Health Sciences Center points out that the U.S. Food & Drug Administration (FDA) had instituted new procedures over the last...
Vioxx, Celebrex, Other Painkillers Up Risks for Heart Failure, Heart Attack Patients
Nov 12, 2008 | Parker Waichman Alonso LLP
Vioxx, Celebrex, ibuprofen and other NSAID painkillers increase the chances that heart attack and heart failure patients will experience a second heart attack or death, a new study says. According to Danish researchers, the risk of a second heart attack or death actually doubled within the first 90 days of starting Vioxx or Celebrex. Other painkillers, like ibuprofen, increased the risk between 2.1 and 1.3 times. The study was presented this week at the American Heart Association...
COX-2 Inhibitors More Likely to Raise Heart Risks Than Other NSAIDs
Nov 5, 2008 | Parker Waichman Alonso LLP
A new study that confirms the heart risks associated with a class of drugs called NSAIDs has found that the increased risk correlates to the specific pain-causing molecule they act against. According to the study, NSAIDS that are cox-2 inhibitors are more likely to increase the risks of heart attacks and strokes. NSAIDs are the most prescribed medications for treating conditions such as arthritis. Most people are familiar with over-the-counter, nonprescription NSAIDs, such as...
Pfizer Announces Bextra, Celebrex Settlement
Oct 17, 2008 | Parker Waichman Alonso LLP
Pfizer has reached a tentative agreement to settle lawsuits involving its Bextra and Celebrex painkillers for $894 million. If it goes forward, the Pfizer Bextra and Celebrex settlement will resolve roughly 90 percent of the personal injury lawsuits the company faces because of the drugs.Celebrex and Bextra are COX-2 inhibitors, a class of drugs that also includes Merck’s recalled Vioxx. Such medications are linked to an increased risk of blood clots, heart attacks and...
Vioxx Heart Risks Long-Lasting
Oct 14, 2008 | Parker Waichman Alonso LLP
Heart risks from Vioxx, the defective painkiller pulled from the market in 2004, lingered long after many patients stopped taking the drug. According to a report in The Washington Post, a study conducted by researchers at the M.D. Anderson Cancer Center in Houston, TX found that Vioxx increased the risk of heart attack and stroke by "close to twofold, and the risk persisted for approximately a year". The authors of the study, which was published online by the journal Lancet,...
Vioxx
Vioxx FDA Information
FDA Drug Information Facts
VIOXX (Rofecoxib) FDA INFORMATION
The FDA issued several warnings concerning Vioxx related side effects before the drug was removed from the market.. The links below will redirect you to these warnings on the FDA website.
- 2001 Merck Vioxx VIGOR Study
- 2001 Vioxx Advertising Warning Letter
- 2002 FDA Vioxx Talk Paper
- 2002 Merck Vioxx Dear Doctor Letter
- 2002 Vioxx Safety Label Update
- 2004 FDA Vioxx Recall Advisory
- 2004 FDA Vioxx COX II Q&A
- 2004 FDA Statement on Vioxx
- 2004 FDA Vioxx David Graham Statement
- 2004 Vioxx- Drug Safety Controversy
- 2005 FDA Vioxx Timeline
- 2005 FDA-Vioxx Cardiovascular Safety
Quick Facts
Vioxx Reference Guide
Generic Name
Rofecoxib
Date Approved
May 20, 1999
Manufacturer
Merck & Co.
Status
Withdrawn 9/30/04
Approved Uses
Arthritis
Muscle pain
Off Label Uses
Bone pain
Muscle pain
General pain
Serious Side Effects
Heart attacks
Blood clots
Stroke
Related Topics
Bextra
Celebrex
Mobic
Blood Clots
Heart Attacks
Stroke
Defective Drugs
Diseases
News Feeds
WE ALSO OFFER OUR FIRM NEWS AS RSS/XML FEEDS.
LEARN MORE ABOUT RSS
